NASDAQ$IMVT
Immunovant Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of fiscal year 2021 and paused clinical trials for IMVT-1401 due to safety concerns.
Immunovant reported a net loss of $31.8 million for the quarter ended December 31, 2020, and ended the quarter with approximately $422 million in cash. The company voluntarily paused dosing in its clinical trials for IMVT-1401 due to elevated cholesterol levels.
- R&D expenses increased to $21.1 million, driven by expansion of clinical trial programs.
- G&A expenses increased to $10.5 million, primarily due to personnel-related costs.
- Net loss was $31.8 million, or $0.32 per common share.
- Company ended the quarter with approximately $422 million in cash.
Headline financials
Revenue & EPS history
Immunovant · Revenue · Quarterly
$0
Forward guidance
Immunovant expects to continue development of IMVT-1401 and plans to progress discussions with regulatory authorities. The company expects to provide a further update on its current and future indications and timelines in the second quarter of calendar year 2021.
Tailwinds
- Expect to continue development of IMVT-1401
- Plan to progress discussions with regulatory authorities
- Expect to provide a further update on current and future indications and timelines
- Program-wide data review with input from external scientific experts
- Continue development of IMVT-1401
Headwinds
- Voluntarily paused dosing in clinical trials for IMVT-1401
- Elevated total cholesterol and LDL levels observed in patients treated with IMVT-1401
- Uncertainty regarding the impact of lipid findings
- Potential delays in clinical development plans and timelines due to COVID-19 pandemic
- Actions by regulatory authorities with respect to Immunovant’s product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+0.6%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+2.2%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+35.1%
Q4 2027
Best reaction
-34.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +35.1% | — | — | |
| Q3 2026 | +12.4% | +7.8% | +10.8% | |
| Q2 2026 | +0.0% | +1.7% | +0.9% | |
| Q1 2026 | -4.5% | -1.6% | +4.8% | |
| Q4 2025 | -0.2% | +3.0% | +8.1% | |
| Q3 2025 | -9.6% | -14.1% | -11.1% | |
| Q2 2025 | -2.5% | -6.8% | -8.9% | |
| Q1 2025 | +1.0% | +9.4% | +25.9% | |
| Q4 2024 | -7.1% | -11.3% | -7.1% | |
| Q3 2024 | +4.0% | +4.6% | -10.4% | |
| Q2 2024 | -2.3% | +4.7% | +17.4% | |
| Q1 2024 | +7.4% | -1.9% | +11.5% | |
| Q4 2023 | +4.9% | -0.8% | -5.1% | |
| Q3 2023 | +0.7% | +2.0% | -6.9% | |
| Q2 2023 | +6.3% | -2.1% | +23.2% | |
| Q1 2023 | +19.4% | +24.7% | +23.7% | |
| Q4 2022 | -12.6% | -20.4% | +0.2% | |
| Q3 2022 | -2.7% | -2.5% | -8.8% | |
| Q2 2022 | +1.1% | -0.3% | -12.8% | |
| Q1 2022 | +4.4% | +1.7% | +15.5% | |
| Q4 2021 | -34.6% | -34.5% | -25.0% | |
| Q3 2021 | -13.6% | -18.6% | -25.0% | |
| Q2 2021 | +3.1% | +7.3% | -4.0% | |
| Q1 2021 | +3.7% | +2.3% | +40.2% | |
| Q4 2020 | -11.0% | -13.5% | -14.2% | |
| Q3 2020 | +12.5% | +13.2% | +1.3% | |
| Q2 2020 | +0.1% | +0.1% | +13.9% | |
| Q1 2020 | +0.0% | +0.0% | +0.6% | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro